Growth Metrics

Lucid Diagnostics (LUCD) Net Income towards Common Stockholders (2020 - 2026)

Lucid Diagnostics filings provide 5 years of Net Income towards Common Stockholders readings, the most recent being -$16.3 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 40.94% to -$16.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$70.6 million, a 33.05% decrease, with the full-year FY2025 number at -$70.6 million, down 33.09% from a year prior.
  • Net Income towards Common Stockholders hit -$16.3 million in Q4 2025 for Lucid Diagnostics, down from -$10.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.7 million in Q1 2021 to a low of -$36.0 million in Q1 2025.
  • Median Net Income towards Common Stockholders over the past 5 years was -$11.9 million (2022), compared with a mean of -$13.0 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: plummeted 235.89% in 2022 and later increased 28.32% in 2025.
  • Lucid Diagnostics' Net Income towards Common Stockholders stood at -$11.3 million in 2021, then tumbled by 32.04% to -$14.9 million in 2022, then increased by 27.45% to -$10.8 million in 2023, then dropped by 6.57% to -$11.5 million in 2024, then plummeted by 40.94% to -$16.3 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$16.3 million (Q4 2025), -$10.4 million (Q3 2025), and -$7.9 million (Q2 2025) per Business Quant data.